Divis Labs - Divi's Laboratories Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Divis Labs - Divi's Laboratories Share Price

6,699.0060.50 (0.92%)

Live
As On: 11 Jun, 2026, 11:28 AM IST
As On: 11 Jun, 2026, 11:29 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	6,635.00
High	6,720.00
Low	6,625.00
Prev Close	6,638.50
Volume	72,282
VWAP(₹)	6,695.79

Key Metrics

PE Ratio(x)	69.37
EPS - TTM(₹)	96.73
MCap(₹ Cr.)	1,77,797
MCap Rank	2
PB Ratio(x)	10.51
Div Yield(%)	0.45
Face Value(₹)	2.00
52W High(₹)	7,071.50
52W Low(₹)	5,636.50
MCap/Sales	14.92
Beta(1 Month)	1.54
BV/Share(₹)	631.37

Divis Labs share price insights

Rank 249 - ET 5002025 ranking

Dividend Announcement
Company announced a dividend of Rs 30.0 per share on May 25, 2026 with record date of Jul 24, 2026.
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 13.95% outperformed its 3 year CAGR of 10.79%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 13.66% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Divis Labs Share Price Update
Divi's Laboratories Ltd. share price moved up by 0.92% from its previous close of Rs 6,638.50. Divi's Laboratories Ltd. stock last traded price is 6,699.00
Share Price Value
Today/Current/Last 6,699.006,691.80
Previous Day 6,638.506,638.90

Found Insights useful?

Divis Labs Share Price Returns

1 Day	0.92%
1 Month	-0.22%
3 Months	5.45%
1 Year	-0.3%
3 Years	95.38%
5 Years	54.55%

Divis Labs Share Recommendations

Mean recosCurrent

HOLD

27 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	6	6	7	7
Buy	7	7	7	7
Hold	5	5	4	5
Sell	6	6	7	6
Strong Sell	3	3	2	3
# Analysts	27	27	27	28

Recent Recos

Target₹4500
OrganizationICICI Securities
SELL

Target₹3742
OrganizationICICI Direct
BUY

Target₹3762
OrganizationICICI Direct
BUY

View all Stock Recommendations

News & Analysis

View all Divis Labs Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	2,986.00	2,692.00	2,860.00	2,529.00	2,671.00
Total Income Growth (%)	10.92	-5.87	13.09	-5.32	11.25
Total Expenses	2,017.00	1,906.00	1,940.00	1,793.00	1,806.00
Total Expenses Growth (%)	5.82	-1.75	8.20	-0.72	7.82
EBIT	969.00	786.00	920.00	736.00	865.00
EBIT Growth (%)	23.28	-14.57	25.00	-14.91	19.15
Profit after Tax (PAT)	751.00	583.00	689.00	545.00	662.00
PAT Growth (%)	28.82	-15.38	26.42	-17.67	12.39
EBIT Margin (%)	32.45	29.20	32.17	29.10	32.38
Net Profit Margin (%)	25.15	21.66	24.09	21.55	24.78
Basic EPS (₹)	28.34	21.98	25.97	20.49	24.93

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	2,947.00	2,665.00	2,806.00	2,476.00	2,623.00
Total Income Growth (%)	10.58	-5.02	13.33	-5.60	10.26
Total Expenses	1,970.00	1,861.00	1,878.00	1,726.00	1,762.00
Total Expenses Growth (%)	5.86	-0.91	8.81	-2.04	6.85
EBIT	977.00	804.00	928.00	750.00	861.00
EBIT Growth (%)	21.52	-13.36	23.73	-12.89	17.95
Profit after Tax (PAT)	756.00	598.00	696.00	557.00	667.00
PAT Growth (%)	26.42	-14.08	24.96	-16.49	12.29
EBIT Margin (%)	33.15	30.17	33.07	30.29	32.83
Net Profit Margin (%)	25.65	22.44	24.80	22.50	25.43
Basic EPS (₹)	28.53	22.56	26.24	20.95	25.12

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	11,067.00	9,712.00	8,184.00	8,112.17	9,073.70
Total Revenue Growth (%)	13.95	18.67	0.89	-10.60	29.04
Total Expenses	7,605.00	6,796.00	6,021.00	5,743.54	5,390.20
Total Expenses Growth (%)	11.90	12.87	4.83	6.56	23.46
Profit after Tax (PAT)	2,568.00	2,191.00	1,600.00	1,823.38	2,960.45
PAT Growth (%)	17.21	36.94	-12.25	-38.41	49.19
Operating Profit Margin (%)	33.00	31.17	27.60	30.50	41.12
Net Profit Margin (%)	24.31	23.40	20.39	23.47	33.04
Basic EPS (₹)	96.75	82.53	60.27	68.69	111.52

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	10,894.00	9,550.00	8,002.00	7,974.31	8,991.08
Total Revenue Growth (%)	14.07	19.35	0.35	-11.31	31.04
Total Expenses	7,384.00	6,621.00	5,870.00	5,620.21	5,314.56
Total Expenses Growth (%)	11.52	12.79	4.44	5.75	25.54
Profit after Tax (PAT)	2,607.00	2,209.00	1,576.00	1,808.15	2,948.54
PAT Growth (%)	18.02	40.16	-12.84	-38.68	50.84
Operating Profit Margin (%)	34.01	31.85	27.85	30.87	41.41
Net Profit Margin (%)	25.09	24.01	20.56	23.71	33.20
Basic EPS (₹)	98.19	83.20	59.37	68.11	111.07

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 13.95% outperformed its 3 year CAGR of 10.79%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 13.66% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	20,033.00	16,932.00	15,470.00	14,438.77	13,374.71
Total Assets Growth (%)	18.31	9.45	7.14	7.96	24.14
Total Liabilities	3,272.00	1,963.00	1,899.00	1,671.68	1,646.53
Total Liabilities Growth (%)	66.68	3.37	13.60	1.53	11.29
Total Equity	16,761.00	14,969.00	13,571.00	12,767.09	11,728.18
Total Equity Growth (%)	11.97	10.30	6.30	8.86	26.18
Current Ratio (x)	5.43	6.94	7.57	8.46	6.99
Total Debt to Equity (x)	0.00	0.00	0.00	0.00	0.00
Contingent Liabilities	0.00	1,841.00	1,432.00	736.98	1,259.90

Annual	FY 2026	FY 2025	FY 2023	FY 2023	FY 2022
Total Assets	19,954.00	16,824.00	14,351.62	15,362.00	13,307.86
Total Assets Growth (%)	18.60	9.52	7.84	7.04	24.10
Total Liabilities	3,243.00	1,929.00	1,646.20	1,878.00	1,616.51
Total Liabilities Growth (%)	68.12	2.72	1.84	14.08	11.31
Total Equity	16,711.00	14,895.00	12,705.42	13,484.00	11,691.35
Total Equity Growth (%)	12.19	10.46	8.67	6.13	26.10
Current Ratio (x)	5.47	7.03	8.56	7.60	7.10
Total Debt to Equity (x)	0.00	0.00	0.00	0.00	0.00
Contingent Liabilities	0.00	1,841.00	736.98	1,432.00	1,259.90

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	2,738.00	1,653.00	1,261.00	2,459.73	1,911.80
Net Cash used in Investing Activities	-2,219.00	-804.00	-269.00	-2,707.62	-2,194.92
Net Cash flow from Financing Activities	-804.00	-799.00	-799.00	-797.17	-532.44
Net Cash Flow	-285.00	50.00	193.00	-1,045.06	-815.56
Closing Cash & Cash Equivalent	128.00	413.00	363.00	169.70	1,214.76
Closing Cash & Cash Equivalent Growth (%)	-69.01	13.77	113.91	-86.03	-40.17
Total Debt/ CFO (x)	0.00	0.00	0.00	0.00	0.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	2,711.00	1,650.00	1,266.00	2,447.95	1,910.16
Net Cash used in Investing Activities	-2,218.00	-803.00	-268.00	-2,706.75	-2,195.40
Net Cash flow from Financing Activities	-802.00	-797.00	-798.00	-796.59	-531.50
Net Cash Flow	-309.00	50.00	200.00	-1,055.39	-816.74
Closing Cash & Cash Equivalent	85.00	394.00	344.00	144.17	1,199.56
Closing Cash & Cash Equivalent Growth (%)	-78.43	14.53	138.61	-87.98	-40.51
Total Debt/ CFO (x)	0.00	0.00	0.00	0.00	0.00

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 2219.0 cr for investing activities which is an YoY increase of 176.0%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	15.32	14.63	11.78	14.28	25.24
Return on Capital Employed (%)	19.37	18.85	15.26	17.76	30.25
Return on Assets (%)	12.81	12.93	10.34	12.62	22.13
Interest Coverage Ratio (x)	171.65	1,660.00	848.00	4,048.48	4,994.76
Asset Turnover Ratio (x)	0.57	0.58	0.52	0.56	0.74
Price to Earnings (x)	61.73	69.93	57.14	41.15	39.53
Price to Book (x)	9.40	10.22	6.71	5.88	9.97
EV/EBITDA (x)	39.05	44.96	34.24	26.10	28.55
EBITDA Margin (%)	37.38	35.47	32.42	34.92	44.59

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	15.60	14.83	11.68	14.23	25.21
Return on Capital Employed (%)	19.69	19.02	15.13	17.73	30.29
Return on Assets (%)	13.06	13.13	10.25	12.59	22.15
Interest Coverage Ratio (x)	173.65	3,331.00	837.00	5,185.94	6,134.95
Asset Turnover Ratio (x)	0.56	0.57	0.52	0.55	0.74
Price to Earnings (x)	60.61	69.44	57.80	41.49	39.68
Price to Book (x)	9.43	10.27	6.75	5.90	10.00
EV/EBITDA (x)	38.61	44.82	34.69	26.26	28.61
EBITDA Margin (%)	38.44	36.21	32.75	35.36	44.90

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
47%
Positive Movement
since 1st Jan 2005
on basis
53%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 6765.67 Pivot
6687.83
S1 6560.67
R2 6892.83 S2 6482.83
R3 7097.83 S3 6277.83
Average True Range
5 Days 14 Days 28 Days
183.81 165.41 158.34

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Divis Labs	69.37	10.63	15.32	19.37	12.81	10.79	33.00	24.31	96.75	5.43	0.00	0.00
Torrent Pharma	71.46	8.79	25.78	9.30	4.88	12.70	23.93	15.29	63.92	1.13	1.76	4.90
Cipla	28.81	3.24	11.26	15.65	9.12	7.65	19.72	13.74	48.03	3.44	0.01	0.07
Cadila Healthcare	22.02	3.75	18.58	20.64	9.61	16.47	27.90	18.51	50.09	1.27	0.43	5.56
Dr. Reddys	25.40	2.79	11.07	13.90	7.21	10.76	17.07	12.29	50.41	1.80	0.17	1.11
Add More

Annual Ratios (%)

Choose from Peers

Lupin
Mankind Pharma
Aurobindo Pharma
Biocon
Alkem Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 13,77,35,090 51.88 % 0.00
Pledge 0 0.00 % 0.00
FII 5,38,65,707 20.29 % 0.21
DII 5,05,76,802 19.05 % -0.08
MF 3,56,36,887 13.42 % -0.31
Others 2,32,90,981 8.78 % -0.11
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 51.88 51.88 51.89 51.89
Pledge 0.00 0.00 0.00 0.00
FII 20.29 20.08 19.39 19.74
DII 19.05 19.14 19.62 18.93
Mutual Funds 13.42 13.73 13.99 13.31
Others 8.78 8.89 9.09 9.43

Mutual Funds Ownership

MF Ownership as on 30 April 2026

SBI Equity Hybrid Direct-G
Hybrid: Aggressive Hybrid
4
- 2,145.82
  Amount Invested (in Cr.)
- 2.57%
  % of AUM
- 0.00
  % Change (MoM basis)
SBI Large Cap Direct-G
Equity: Large Cap
4
- 1,321.32
  Amount Invested (in Cr.)
- 2.47%
  % of AUM
- 0.00
  % Change (MoM basis)
HDFC Flexi Cap Direct-G
Equity: Flexi Cap
5
- 1,171.14
  Amount Invested (in Cr.)
- 1.17%
  % of AUM
- 4.49
  % Change (MoM basis)

View all Mutual Fund Schemes

Divis Labs Futures & Options

Type
Expiry Month
Strike Price

Date	Price	Open Interest
30-06-2026Current	116.8024.55 (26.61%)	66,4007,700 (13.12%)
102.05 Open	133.75 High	101.45 Low
92.25 Close	117 Contracts Traded	3,220.87 Turnover (₹ Lakhs)

Open Interest as of 11 Jun 2026

Expiry MonthPlease select expiry month:

Date	Price	Open Interest
30-06-2026Current	6,724.5050.50 (0.76%)	28,95,800-6,000 (-0.21%)
6,679.50 Open	6,749.00 High	6,677.50 Low
6,674.00 Prev Close	176 Contracts Traded	4,730.07 Turnover (₹ Lakhs)

Open Interest as of 11 Jun 2026

Divis Labs Top Searches

Corporate Actions

Recent
General Meeting
-
May 25, 2026
Final
1500%
May 25, 2026
Board Meeting
Audited Results & Dividend
May 14, 2026

Announced on	Meeting on
May 14, 2026	May 23, 2026
Audited Results & Dividend
Jan 30, 2026	Feb 11, 2026
Quarterly Results
Oct 27, 2025	Nov 07, 2025
Quarterly Results
Jul 28, 2025	Aug 06, 2025
Quarterly Results
May 08, 2025	May 17, 2025
Audited Results & Dividend

Dividends
Announced on Ex-Date Dividend%
May 25, 2026 Jul 24, 2026 1500%
May 19, 2025 Jul 25, 2025 1500%
May 27, 2024 Aug 02, 2024 1500%
May 22, 2023 Aug 11, 2023 1500%
May 23, 2022 Aug 11, 2022 1500%
Bonus
Announced on Ex-Date
Aug 08, 2015 Sep 23, 2015
Bonus Ratio: 1 share(s) for every 1 shares held
Jun 06, 2009 Jul 30, 2009
Bonus Ratio: 1 share(s) for every 1 shares held
Splits
Announced on Ex-Date
May 23, 2007 Aug 03, 2007
Split: Old FV10.0| New FV:2.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 25, 2026 Aug 10, 2026
-
May 19, 2025 Aug 11, 2025
-
Feb 04, 2025 Mar 08, 2025
-
Jul 15, 2024 Aug 12, 2024
-
Mar 04, 2024 Apr 06, 2024
-

About Divis Labs

Divi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 1,76,231.32 Crore) operating in Pharmaceuticals sector.

Divi's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Scrap, Sale of services and Export Incentives for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 2,986.00 Crore, up 10.92 % from last quarter Total Income of Rs 2,692.00 Crore and up 11.79 % from last year same quarter Total Income of Rs 2,671.00 Crore. Company has reported net profit after tax of Rs 751.00 Crore in latest quarter.

The company’s top management includes Dr.Ramesh B V Nimmagadda, Dr.Murali K Divi, Dr.Kiran S Divi, Ms.Nilima Prasad Divi, Dr.S Devendra Rao, Mr.N V Ramana, Mr.K V Chowdary, Dr.Rajendra Kumar Premchand, Prof.S Ganapaty, Prof.Sunaina Singh, Mr.L Kishore Babu, Mr.M Satish Choudhury. Company has Price Waterhouse Chartered Accountants LLP as its auditors. As on 31-03-2026, the company has a total of 26.55 Crore shares outstanding.

Divis Labs Share Price Today is Rs. 6699.00. On previous day, the Divis Labs Share Price (NSE) closed at Rs. 6753.0, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 51.88% of the stake in Divis Labs shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Divis Labs stocks was 20.29% as compared to 20.08% in Dec 2025 with increase of 0.21%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 19.05% as compared to 19.14% in Dec 2025 with decrease of 0.09%. Out of the total DII holdings in Divis Labs shares 13.42% was held by mutual funds. The rest including public held is 8.78%. Divis Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Divis Labs Dividend: Ever since 1990, Divis Labs dividends has been paid out around 24 times. As on 11 Jun, 2026, 11:28 AM IST, The overall dividend yield for Divis Labs stands at 0.44%. The last dividend paid was on July 24, 2026 (Rs. 30.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 96.73.

Divis Labs Bonus: The most recent bonus issue had been in year September 23, 2015 around 10 years ago at 1 : 1 ratio. The first bonus issue was announced in Jun 2009.

Stock Forecast:
After showing 2986.0 Cr. of sales and 10.92% of quarterly net profit, there have been multiple ups and downs in the Divis Labs stock prices in the past few weeks. For example, Divis Labs stock price on 3rd of June 2026 was around Rs. 6576.5. Divis Labs share price now stands at an average of Rs. 6699.00. Judging by last week's performance, stock is in up trend.

Divis Labs has a median target price of Rs. 7003.23 in 12 months by 26 analysts. They have provided a high estimate of Rs. 9450.0 and low estimate of Rs. 4486.0 for Divis Labs share.

Historical Prices and Performance:
Divis Labs, incorporated in 1990 is a Large Cap company (with a market cap of Rs. 176231.32) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Divis Labs stock was 15.32%, 14.63%, 11.78%, 14.28% and 25.24% respectively.
The Divis Labs share gave a 3 year return of 93.61% as compared to Nifty 50 which gave a return of 25.06%.
Divis Labs announced 1500.0% final dividend on July 24, 2026.

Key Metrics:
PE Ratio of Divis Labs is 69.81
Prices/Sales Ratio of Divis Labs is 14.92
Price/Book Ratio of Divis Labs is 10.7

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Divis Labs, major competitors and peers include Torrent Pharma, Cipla, Cadila Healthcare and Dr. Reddys. As of Dec 2025, the dividend yield of Divis Labs stands at 0.44% while Torrent Pharma, Cipla, Cadila Healthcare and Dr. Reddys stand at 0.85%, 0.94%, 0.09% and 0.63% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 69.81 and 10.7 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 27, Three months ago this number stood at 28. Out of total, 6 analyst have a'Strong Buy' reco, 7 analyst have a'Buy' reco, 5 analyst have a'Hold' reco, 6 analyst have a'Sell' reco.

Mean recommendations by 27 analyst stand at'Buy'.

Leadership of Divis Labs :
M Satish Choudhury is Co. Secretary & Compl. Officer
L Kishore Babu is Chief Financial Officer
Ramesh B V Nimmagadda is Non Exe.Chairman&Ind.Director
Murali K Divi is Managing Director
Kiran S Divi is WholeTime Director & CEO
Nilima Prasad Divi is Whole Time Director
S Devendra Rao is Whole Time Director
N V Ramana is Executive Director
K V Chowdary is Independent Director
S Ganapaty is Independent Director
Sunaina Singh is Independent Director
Rajendra Kumar Premchand is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Next 50, Nifty 100, Nifty 200, Nifty 500, BSE 500

Address

Divi Towers,1-72/23(P)/DIVIS/303,Cyber Hills, Gachibowli,Hyderabad, Telangana - 500032

Contact

mail@divislabs.com

http://www.divislabs.com

Executive Leadership

RB

Ramesh B V Nimmagadda

Non Exe.Chairman&Ind.Director

MK

Murali K Divi

Managing Director

KS

Kiran S Divi

WholeTime Director & CEO

NP

Nilima Prasad Divi

Whole Time Director

Show More

Auditors

Price Waterhouse Chartered Accountants LLP

Brands

FAQs about Divis Labs share

1. What's Divis Labs share price today and what are Divis Labs share returns ?
Divis Labs share price is Rs 6,699.00 as on 11 Jun, 2026, 11:28 AM IST. Divis Labs share price is up by 0.92% based on previous share price of Rs. 6753.0.
2. What are the returns for Divis Labs share?
Return Performance of Divis Labs Shares:
- 1 Week: Divis Labs share price moved up by 1.55%
3. What's the market capitalization of Divis Labs?
Within the Pharmaceuticals sector, Divis Labs stock has a market cap rank of 2. Divis Labs has a market cap of Rs 1,77,798 Cr.
4. What has been highest price of Divis Labs share in last 52 weeks?
52 Week high of Divis Labs share is Rs 7,071.50 while 52 week low is Rs 5,636.50
5. What is the PE & PB ratio of Divis Labs?
The PE ratio of Divis Labs stands at 68.63, while the PB ratio is 10.5.

Top Gainers

As on 11:27 AM | 11 Jun 2026

Aegis Logistics

887.80

86.80 (10.84%)

Blue Jet Healthcare

509.10

39.36 (8.38%)

DOMS Industries

2,235.40

116.81 (5.52%)

581.20

30.41 (5.52%)

1,933.10

100.10 (5.47%)

Top Losers

As on 11:27 AM | 11 Jun 2026

1,817.70

-73.90 (-3.91%)

1,147.20

-46.21 (-3.88%)

168.35

-6.56 (-3.75%)

Afcons Infrastru

318.80

-11.25 (-3.41%)

158.30

-5.32 (-3.26%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.